The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Eli Lilly reported third-quarter earnings and revenue below Wall Street expectations, reducing its full-year adjusted profit outlook. The pharmaceutical company cited weaker sales of its weight loss ...

Aktis Oncology, which is headquartered in Boston but a significant presence in North Carolina ... investors Bristol Myers Squibb (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), and MRL Ventures ...

Eli Lilly & Co. lowered guidance on lackluster sales of its blockbuster weight-loss drug Zepbound and diabetes drug Mounjaro. Madison Muller reports on "Bloomberg Open Interest." ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

The S&P 500 fell 0.3 per cent, as heavyweight Eli Lilly led declines among several healthcare ... Vice-president Kamala ...

Eli Lilly has raised its revenue guidance for ... In its update, Ricks said a new facility at Concord in North Carolina – part of an $18 billion investment programme launched in 2020 – is ...

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...